| CreditFlow: End of Day (Europe IG) | Sep 23, 2026 |
| CreditFlow: End of Day (Europe IG) | Sep 22, 2026 |
| CreditFlow: End of Day (Europe IG) | Sep 14, 2026 |
| CreditFlow: End of Day (Europe IG) | Aug 27, 2026 |
| CreditFlow: End of Day (Europe IG) | Aug 26, 2026 |
| CreditFlow: End of Day (Europe IG) | Aug 24, 2026 |
| CreditFlow: End of Day (Europe IG) | Jul 1, 2026 |
| CreditFlow: End of Day (Europe IG) | Jun 12, 2026 |
| CreditFlow: End of Day (Europe IG) | Jun 2, 2026 |
| CreditFlow: End of Day (Europe IG) | May 27, 2026 |
| Industry | Status | Date | Ticker(s) | issuer(s) | MO | SP | FI | Size (M) | Ranking | TNR | Call | MTY | Coupon | Leads | product | Region | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
HLTH | PRCD | Sep 23, 2026 | BAYNGR | Bayer AG | Baa3 | BB+ | BB+ | €1,000 | Subordinated | 30.00 | 6.00 | Sep-56 | 5.75% | IGC | EMEA | ||||
HLTH | PRCD | Sep 23, 2026 | BAYNGR | Bayer AG | Baa3 | BB+ | BB+ | €1,000 | Subordinated | 30.00 | 9.00 | Sep-56 | 6.25% | IGC | EMEA | ||||
HLTH | PRCD | Sep 22, 2026 | BUPFIN | Bupa Finance PLC | Baa1 | - | BBB | £300 | Tier 2 | 12.00 | - | Sep-38 | 6.875% | IGC | EMEA | ||||
HLTH | PRCD | Sep 14, 2026 | SDZSW | Sandoz Finance BV | Baa2 | BBB | - | €500 | Sr. Unsecured | 12.00 | - | Sep-38 | 4.835% | IGC | EMEA | ||||
HLTH | PRCD | Sep 9, 2026 | SNLN | Smith & Nephew PLC | Baa1 | BBB+ | BBB+ | $700 | Sr. Unsecured | 10.00 | - | Sep-36 | 5.75% | IGC | EMEA | ||||
HLTH | PRCD | Sep 9, 2026 | TEVA | Teva Pharmaceutical Finance Netherlands II BV | Baa3 | BBB- | BBB- | €1,000 | Sr. Unsecured | 6.50 | - | Mar-33 | 4.25% | IGC | EMEA | ||||
HLTH | PRCD | Sep 9, 2026 | TEVA | Teva Pharmaceutical Finance Netherlands II BV | Baa3 | BBB- | BBB- | €500 | Sr. Unsecured | 10.00 | - | Sep-36 | 4.625% | IGC | EMEA | ||||
HLTH | PRCD | Sep 9, 2026 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Baa3 | BBB- | BBB- | $1,200 | Sr. Unsecured | 5.25 | - | Jan-32 | 5.25% | IGC | EMEA | ||||
HLTH | PRCD | Sep 9, 2026 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Baa3 | BBB- | BBB- | $1,000 | Sr. Unsecured | 7.25 | - | Jan-34 | 5.50% | IGC | EMEA | ||||
HLTH | PRCD | Sep 9, 2026 | TEVA | Teva Pharmaceutical Finance Netherlands III BV | Baa3 | BBB- | BBB- | $1,000 | Sr. Unsecured | 10.25 | - | Jan-37 | 5.75% | IGC | EMEA |